Opendata, web and dolomites

PROT-RESIST SIGNED

Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inhibiting Metastasis in Prostate and Pancreatic Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROT-RESIST project word cloud

Explore the words cloud of the PROT-RESIST project. It provides you a very rough idea of what is the project "PROT-RESIST" about.

antimetastatic    clinicians    opinion    direct    ip    metastasis    indications    invasion    binding    intervention    planning    protein    translated    appi    translation    feedback    potency    final    human    precursor    perform    contribution    standard    clearance    protease    parallel    attractive    evolution    therapies    proteolytic    commercialization    enhanced    ongoing    promotes    3m    anti    treatments    agents    neoadjuvant    serine    deaths    protocols    cell    engineered    clinical    poc    cancers    adjuvant    resistance    pancreatic    leaders    therapeutic    domain    carry    involvement    site    amyloid    decreasing    scaffold    primary    tumors    prototype    picomolar    medical    feasible    input    windows    optimization    designated    directed    specificity    preclinical    kunitz    stg    confirm    consequently    prostate    cancer    models    therapy    beta    mesotrypsin    tumor    metastatic    soc    experts    distal    inhibitor    erc    progression    market    nevertheless    body    affinity    exhibits    care    generate    urgent    stage   

Project "PROT-RESIST" data sheet

The following table provides information about the project.

Coordinator
BEN-GURION UNIVERSITY OF THE NEGEV 

Organization address
address: .
city: BEER SHEVA
postcode: 84105
website: www.bgu.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BEN-GURION UNIVERSITY OF THE NEGEV IL (BEER SHEVA) coordinator 150˙000.00

Map

 Project objective

Distal site tumor metastasis is the leading cause of prostate- and pancreatic-cancer-related deaths; nevertheless, standard-of-care (SoC) treatments and other targeted therapies under development are based on their activity against the primary tumors rather than on their anti-metastatic activity. There is consequently an urgent medical need for new agents targeting the metastatic process. In prostate and pancreatic cancer models, the serine protease mesotrypsin promotes tumor invasion and metastasis, making it an attractive target for therapeutic intervention. In our ERC StG project, we used directed evolution to generate a novel prototype mesotrypsin inhibitor, designated APPI-3M, which is based on the human amyloid β-protein precursor Kunitz protease inhibitor domain (APPI) scaffold. This inhibitor has picomolar affinity, enhanced binding specificity and improved proteolytic resistance to mesotrypsin and exhibits high potency in cell-based and preclinical models of prostate cancer invasion and metastasis. In this PoC proposal, we propose to perform final lead optimization (particularly decreasing body clearance) of APPI-3M towards its commercialization for clinical translation as an antimetastatic therapeutic adjuvant, with the direct involvement in the planning stage of clinicians and other key opinion leaders in the field. The feedback of these experts is expected to confirm the need to address the problem of metastatic progression and to identify potential indications and therapeutic windows for the use of APPI-3M as a neoadjuvant in prostate and pancreatic cancers. This input will be translated into feasible preclinical studies to demonstrate the contribution of APPI-3M therapy to currently ongoing SoC protocols for prostate and pancreatic cancers. In parallel, we will carry out the in-depth market and IP analyses needed for the commercialization of the engineered protein for therapeutic applications.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROT-RESIST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROT-RESIST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More